Literature DB >> 25085233

Prognostic value of CA4/DG volumetry with 3T magnetic resonance imaging on postoperative outcome of epilepsy patients with dentate gyrus pathology.

Meng Na1, Yanshu Liu2, Chen Shi3, Wenpeng Gao4, Haitao Ge5, Yu Wang6, Haiyang Wang7, Yu Long8, Hong Shen9, Changbin Shi10, Zhiguo Lin11.   

Abstract

PURPOSE: Hippocampal sclerosis (HS), the most common feature of mesial temporal lobe epilepsy (MTLE), is widely accepted as surgical indication for refractory epilepsy. Pathological hallmarks in hippocampal dentate gyrus (DG), including granule cell loss (GCL) and granule cell dispersion (GCD), are known to be closely related to the status epilepticus and spontaneous seizure. Our aim was to assess the association between volumetric changes in the hippocampal CA4/DG determined with 3-Tesla (3T) magnetic resonance imaging (MRI) and the postoperative seizure outcomes in MTLE patients with or without dentate gyrus pathology (DGP).
METHODS: High-resolution T2- and T1-weighted three-dimensional (3D) MRI scans were performed on 39 MTLE patients before surgery with a 3T Philips scanner. ITK-SNAP software was used for segmentation and volumetry of the CA4/DG segment, and NASP software was used for 3D reconstructions of the CA4/DG region. Immunostaining for Neuronal Nuclei (NeuN) was performed on resected hippocampal specimens after surgery to verify the accuracy of CA4/DG segmentation and histopathological changes in DG.
RESULTS: The CA4/DG subfield could be precisely segmented with high-resolution 3T MRI and confirmed by comparison of NeuN-immunoreactive slices with MRI results. MTLE patients with DGP showed smaller CA4/DG volume and favorable postoperative seizure outcomes.
CONCLUSION: The volumetry of CA4/DG was associated with the pathological changes in DG in MTLE patients. The volumetry of CA4/DG with preoperative 3T MRI could predict the postoperative seizure outcomes in those patients.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dentate gyrus pathology; Hippocampal sclerosis; Mesial temporal lobe epilepsy; Postoperative outcome

Mesh:

Year:  2014        PMID: 25085233     DOI: 10.1016/j.eplepsyres.2014.06.005

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  5 in total

Review 1.  Potential Therapeutic Benefits of Honey in Neurological Disorders: The Role of Polyphenols.

Authors:  Arslan Iftikhar; Rimsha Nausheen; Humaira Muzaffar; Muhammad Ahsan Naeem; Muhammad Farooq; Mohsin Khurshid; Ahmad Almatroudi; Faris Alrumaihi; Khaled S Allemailem; Haseeb Anwar
Journal:  Molecules       Date:  2022-05-20       Impact factor: 4.927

2.  Proteome-wide characterization of signalling interactions in the hippocampal CA4/DG subfield of patients with Alzheimer's disease.

Authors:  Jae Ho Kim; Julien Franck; Taewook Kang; Helmut Heinsen; Rivka Ravid; Isidro Ferrer; Mi Hee Cheon; Joo-Yong Lee; Jong Shin Yoo; Harry W Steinbusch; Michel Salzet; Isabelle Fournier; Young Mok Park
Journal:  Sci Rep       Date:  2015-06-10       Impact factor: 4.379

3.  Automated subfield volumetric analysis of hippocampus in temporal lobe epilepsy using high-resolution T2-weighed MR imaging.

Authors:  Daichi Sone; Noriko Sato; Norihide Maikusa; Miho Ota; Kaoru Sumida; Kota Yokoyama; Yukio Kimura; Etsuko Imabayashi; Yutaka Watanabe; Masako Watanabe; Mitsutoshi Okazaki; Teiichi Onuma; Hiroshi Matsuda
Journal:  Neuroimage Clin       Date:  2016-06-13       Impact factor: 4.881

4.  Beneficial Effects of Silibinin Against Kainic Acid-induced Neurotoxicity in the Hippocampus in vivo.

Authors:  Sehwan Kim; Un Ju Jung; Yong-Seok Oh; Min-Tae Jeon; Hyung-Jun Kim; Won-Ho Shin; Jungwan Hong; Sang Ryong Kim
Journal:  Exp Neurobiol       Date:  2017-10-18       Impact factor: 3.261

5.  Morin Prevents Granule Cell Dispersion and Neurotoxicity via Suppression of mTORC1 in a Kainic Acid-induced Seizure Model.

Authors:  Ji Min Lee; Jungwan Hong; Gyeong Joon Moon; Un Ju Jung; So-Yoon Won; Sang Ryong Kim
Journal:  Exp Neurobiol       Date:  2018-06-30       Impact factor: 3.261

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.